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We thank Dr Mubareka and Dr Rubinstein for their thoughtful
commentary [1] related to our recent publication on
aerosolized colistin for the treatment of nosocomial pneumonia
due to multidrug-resistant Gram-negative bacteria in patients
without cystic fibrosis [2]. We would like to provide some
additional clarifications related to the formulation of colistin
used in our study because the commentators state that “… it
is not clear why the more toxic form of colistin was chosen
over the better-tolerated colistin sulphamethate”.
There are two different forms of colistin available for clinical
use. Colistin sulfate is administered orally for bowel decon-
tamination and is administered topically as a powder for the
treatment of bacterial skin infections; and colistimethate
sodium (also called colistin methanesulfate, pentasodium
colistimethanesulfate, colistin sulfamethate, and colistin
sulfonyl methate) is administered intravenously and intra-
muscularly [3]. It is obvious that the terminology regarding the
different formulations of colistin may be confusing.
Colistimethate sodium is produced by a sulfomethylation
reaction of colistin in which the primary amine groups of
L-α-γ-diaminobutyric acid are reacted with formaldehyde
followed by sodium bisulfite [4].
Both formulations of colistin (colistin sulfate and
colistimethate sodium) have been used for aerosol
treatment. However, colistimethate sodium is associated
with fewer adverse effects such as chest tightness, throat
irritation, and cough compared with colistin sulfate [5]. The
formulation of colistin that was administered to our patients
was therefore colistimethate sodium (i.e. the less toxic form
of the drug), not colistin sulfate. In fact, the exact trade
names of colistin that were administered to our patients are
stated in our paper [2].
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Authors’ response
S Mubareka and E Rubinstein
We would like to thank the authors for their response to our
editorial [1]. We acknowledge that colistimethate may be
better tolerated from a respiratory point of view. What
remains unknown, however, is the systemic absorption of
inhaled colistin in critically ill patients, particularly in those
with pneumonia in whom the barrier between the alveolar cell
layer and the vascular system may be damaged. It is
appreciated that this parameter may not be determined in a
retrospective study, and these preliminary results suggest
that further research is called for.
High-pressure liquid chromatography has been used to
measure serum levels of colistin in humans [6]. Appreciable
limitations of bioassays exist, particularly where more than one
antimicrobial is administered in the same patient. Since the
publication of this study by Michalopoulos and colleagues, a
retrospective study of 80 adults who received nebulized,
parenteral, and intrathecal colistin has been published [7]. The
use of intrathecal colistin in two patients highlights its
expanding use and reinforces the need to further our
understanding of the pharmacodynamics of this drug.
Although microbial eradication has been demonstrated in
some patients receiving colistin, the contribution of other
antimicrobials given concomitantly must be considered. We
agree with the authors’ conclusions that monotherapy with
aerosolized colistin, particularly in this patient population, is
unlikely to be sufficient [2].
Circumstances where colistin is the only feasible therapy are
likely to increase in frequency. These would include infections
with multidrug-resistant Acinetobacter baumanii, Pseudomonas418
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spp. and other non-fermenting Gram-negative rods. Never-
theless, the broader microbiological picture must also be
considered where nosocomial infection with methicillin-
resistant  Staphylococcus aureus and vancomycin-resistant
Entercococcus  spp. is already well established and
continuing to spread. Without the judicious use of anti-
microbials, including colistin, the risk of perpetuating these
organisms and other emerging resistant pathogens will only
increase, particularly in high-risk areas such as intensive care
units.
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